KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.

Kara W Chew, Brooke McGinley, Carlee Moser, Jonathan Z Li, Teresa H Evering, Justin Ritz, Arzhang Cyrus Javan, David Margolis, David A Wohl, Michael D Hughes, Eric S Daar, Judith S Currier, Joseph J Eron, Davey M Smith, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/A5401 Study Team, Study Sites, and Investigators

J Infect Dis 231(1) 131-136

PMID39400063
PMCIDPMC11793053
DOI10.1093/infdis/jiae501
发表日期2024-10-14
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

We explored viral and symptom rebound after coronavirus disease 2019 amubarvimab-romlusevimab monoclonal antibody therapy versus placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal severe acute respiratory syndrome coronavirus 2 polymerase chain reaction testing at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0.5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n = 713) or symptom rebound among participants who initially improved (hazard ratio, 0.95 [95% confidence interval, .52-1.75]; analysis population n = 574); <1% had both viral/symptom rebound.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。